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S UMMA R Y
In 2013, 86% of patients with newly diagnosed
tuberculosis (TB) successfully completed treatment and
were discharged from care. However, long-term studies
in industrialised and resource-poor countries all point to
a higher risk of death in TB survivors than in the general
population. The likely explanation is chronic restrictive
and obstructive lung disease consequent to TB. We call
for better linkages between TB control programmes and
respiratory medicine services, a better understanding of
the burden of respiratory disability at the end of anti-
tuberculosis treatment, and political, programmatic,
clinical and research action to improve the quality of
life of affected patients.
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MR PHIRI, a 35-year-old subsistence farmer from
rural Southern Malawi, has just completed 6 months
of anti-tuberculosis treatment for presumed drug-
susceptible tuberculosis (TB). He was human immu-
nodeficiency virus (HIV) negative when tested at the
time of registration for TB. He attended all his clinic
visits and adhered to his fixed-dose combination of
medications, and as his final sputum smear was
negative for acid-fast bacilli, he was pronounced
cured. In due course, he will contribute to that
impressive global statistic of 85% or higher treatment
success in persons newly diagnosed with TB.1 He no
longer has TB. He was not known to have HIV
infection 6 months previously and is therefore
discharged from care. However, do we really know
how healthy he is? Will he now be able to live a
normal life with a life expectancy equivalent to
someone who has never had TB?
The answer is probably no. In 1995, a cohort of
827 African patients diagnosed with TB in Zomba
District, Malawi, was carefully followed up over 7
years from the time of registration, with visits paid to
their village homes to ascertain whether the patients
were alive or dead.2–4 At the time of registration, the
mean age of the cohort was 35 years (standard
deviation 12), and 77% of the cohort was HIV-
positive; 181 patients were registered with HIV-
negative TB. At 12 months, 124 (68.5%) were
recorded as having completed treatment. Six years
later, only 62 (50%) of these 124 patients were found
to be alive; 57 (46%) were known to have died
during these 6 years, with death having been
ascertained by a visit to the patient’s home. The
remaining five patients were lost to follow-up. As
most of the deaths post-treatment occurred at home,
no information about the cause of death was
available, and verbal autopsy was not carried out.
Much was made at the time about HIV-associated
deaths, as Malawi was then grappling with the
problem of a burgeoning HIV-driven TB epidemic.
However, the National TB Programme (NTP) in
Malawi did express surprise at the high mortality in
HIV-negative patients, with nearly half of a relatively
young cohort dead within 6 years of completing anti-
tuberculosis treatment.
RISK OF DEATH AND LUNG IMPAIRMENT
FOLLOWING ANTI-TUBERCULOSIS TREATMENT
Long-term follow-up studies in industrialised coun-
tries such as the United Kingdom, Denmark, the
United States and Israel have also found that the risk
of death in patients completing anti-tuberculosis
treatment is high, with mortality rates consistently
above those observed in the general population.5–8 In
these studies, the relative risk of death was higher in
males and younger individuals with TB than in the
general population. However, as the authors pointed
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out, the explanation for the higher mortality rates
was speculative, and included premature death from
chronic lung impairment, super-infections, including
bronchopulmonary aspergilloma, lung cancer, liver
disease and other comorbidities known to be associ-
ated with TB such as HIV infection and diabetes
mellitus (DM).
Post-tuberculous lung impairment is one obvious
cause of morbidity and mortality following successful
anti-tuberculosis treatment. Nearly one hundred
years ago, lung function studies in males and females
with TB showed evidence of restrictive lung dis-
ease.9,10 More recent studies have shown that
pulmonary TB (PTB) is associated with largely
irreversible changes to bronchial and parenchymal
structures, leading to distortions in bronchial vascu-
lature, bronchiectasis, emphysema and fibrosis.11–16
A restrictive pattern of lung disease is common and is
independent of tobacco smoking.17 Although pulmo-
nary impairment is more likely after extensive
parenchymal involvement, significant declines may
also be observed in patients with localised PTB.18
Chronic airway obstruction can also be a result of
PTB, and this association has been known about for
over 50 years.19,20 A recent study in Mexico found
that just over one third of patients with a history of
PTB had non-reversible chronic airway obstruction
that was independent of smoking history and
impacted significantly on quality of life.21 Airway
obstruction in these patients was significantly asso-
ciated with extensive pulmonary radiographic chang-
es, residual lung cavities and mediastinal retraction.
However, similar to patients with restrictive airways
disease, TB patients with no sequelae on chest
radiography may also show chronic airway obstruc-
tion and persistent respiratory symptoms.22 In a
large, recently published, international population-
based study by BOLD (the Burden of Obstructive
Lung Disease), the risk of restrictive airways disease
and airflow obstruction in people with a history of
TB was more than twice as high as that found in
persons with no history of TB; this was particularly
apparent in people from low- and middle-income
countries.23
TUBERCULOSIS AND CHRONIC LUNG
IMPAIRMENT IN THE ‘END TB STRATEGY’ AND
SUSTAINABLE DEVELOPMENT GOALS
The aims of anti-tuberculosis treatment, as stated by
the World Health Organization in their 2010
treatment guidelines, are to cure the patient, prevent
death, prevent relapse, reduce transmission of TB and
prevent the development and transmission of drug
resistance.24 The Stop TB (and now the End TB)
strategy generally does a good job in achieving these
aims, with treatment success in newly registered TB
patients worldwide reaching 86% in 2013.1 Howev-
er, within these broad aims there are also explicit
statements about restoring quality of life and
productivity and preventing death from the late
effects of TB.24 Responsibility towards patients with
PTB should not, therefore, end with attainment of
microbiological cure.
The last two decades have seen an inexorable rise in
non-communicable diseases in all countries of the
world, with the global number of deaths from these
diseases increasing from an estimated 27 million in
1990 to nearly 35 million by 2010.25 The term ‘non-
communicable diseases’ covers a large number of
conditions, but the emphasis has been on four main
groups of diseases for the prevention of premature
mortality—cardiovascular disease, cancer, DM and
chronic respiratory disease. In the new Sustainable
Development Goals (SDG), which are set to dominate
global health policy from 2016 to 2030, the fourth
target of the only SDG focusing on health (SDG 3.4)
is ‘to reduce by one third premature mortality from
non-communicable diseases through prevention and
treatment by 2030’.26 Considerable recent attention
has been focused on cardiovascular disease and DM,
although chronic obstructive pulmonary disease is the
third leading cause of mortality worldwide.27 Bron-
chodilators (short-acting and long-acting beta-2
agonists and anti-muscarinics) and anti-inflammato-
ry drugs (inhaled corticosteroids and phosphodiester-
ase inhibitors), either singly or in combination, can
provide symptomatic relief; these effects may be
further augmented by persuading patients to quit
smoking.28
LINKING NATIONAL TUBERCULOSIS
PROGRAMMES TO RESPIRATORY MEDICINE
SERVICES
Given the strong association between TB and
impaired lung function, there needs to be more
thought and discussion about how to better link TB
control programmes with respiratory medicine ser-
vices and a better understanding of the burden of
respiratory disability at the end of anti-tuberculosis
treatment. Approximately 5 million TB patients
complete treatment successfully each year;1 however,
we have no information about the proportion of
patients with respiratory disability, the severity of
lung impairment or the impact on quality of life, or
whether respiratory dysfunction is amenable to
treatment. This needs to change. Already we are
seeing connections, synergies and benefits of inte-
grating care for communicable and non-communica-
ble diseases, with notable examples being DM and TB
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and HIV and cardiovascular disease.29 TB and
chronic respiratory disease need to follow suit.
For a start, NTPs need to systematically reach out
to respiratory physicians, and respiratory physicians
with an interest in TB need to link up with NTPs.
Together these two groups need to work out simple
strategies for assessing patients for lung function at
the end of treatment. In high TB burden countries,
sufficient numbers of trained respiratory physicians
who have the necessary skills to handle the large
patient load will be required. The outreach between
NTPs and respiratory physicians should be combined
with significant advocacy and awareness efforts to
ensure that the rhetoric about linkage is matched with
action.
If lung function is impaired, appropriate treatment
needs to be instituted, and, ideally, patients should
then be regularly followed up. Based on the cohort
analysis reports of case finding and treatment
outcomes, the respiratory disease burden at the end
of anti-tuberculosis treatment can be measured and
plans made for the treatment and management of
patients. Post-treatment connections are not new to
TB control programmes: for example, patients with
HIV-associated TB are often discharged from TB care
at the end of anti-tuberculosis treatment and referred
for long-term HIV care and treatment with antiret-
roviral therapy. Much useful research could be
carried out in this context, particularly in terms of
understanding baseline risk factors that predict long-
term lung damage, which may then be prevented by
earlier diagnosis and, possibly, judicious use of anti-
inflammatory drugs or immune-therapeutic ap-
proaches during anti-tuberculosis treatment.30
TB and chronic lung disease are an example of a
communicable and a non-communicable disease
occurring in the same patient population, although
temporarily related, and we should not ignore the
long-term consequences of this infectious disease. To
be effective, we will need to harness and secure
political, programmatic, clinical and research com-
mitment for integrated and sustainable action.
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R E S U M E
En 2013, 86% des patients avec une tuberculose (TB)
re´cemment diagnostique´e ont acheve´ avec succe`s leur
traitement et ont termine´ leur prise en charge.
Cependant, les e´tudes a` long terme dans des pays
industrialise´s et des pays a` faibles ressources soulignent
un risque majore´ de de´ce`s chez les survivants de la TB
par comparaison a` la population ge´ne´rale. L’explication
plausible est une atteinte chronique restrictive et
obstructive des poumons conse´cutive a` la TB. Nous
plaidons pour de meilleurs liens entre les programmes de
lutte contre la TB et les services de pneumologie, pour
une meilleure compre´hension du poids des atteintes
respiratoires a` la fin du traitement antituberculeux et
pour une action politique, programmatique, clinique et
de recherche afin d’ame´liorer la qualite´ de vie des
patients affecte´s.
R E S UM E N
En el 2013, 86% de los pacientes con un nuevo
diagno´stico de tuberculosis (TB) completaron
eficazmente el tratamiento y se dieron de alta del
programa de atencio´n. Sin embargo, los estudios a
largo plazo en paı´ses industrializados y en paı´ses con
escasos recursos indican un mayor riesgo de muerte en
los pacientes que sobreviven a un episodio de TB, al
compararlos con la poblacio´n general. Una explicacio´n
posible es la aparicio´n de enfermedad pulmonar
restrictiva u obstructiva como consecuencia de la TB.
El artı´culo recomienda establecer vı´nculos ma´s eficaces
entre los programas de control de la TB y los servicios de
neumologı´a, mejorar la comprensio´n de la carga de
morbilidad por discapacidad respiratoria al final del
tratamiento antituberculoso y adoptar medidas
polı´ticas, programa´ticas, clı´nicas y de investigacio´n
encaminadas a mejorar la calidad de vida de los
pacientes afectados.
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